Eikon's EIK1001 Hits 63.1% ORR in First-Line NSCLC at ESMO 2026

summarizeSummary

At ESMO 2026, Eikon reported updated TeLuRide-005 data showing that EIK1001 plus pembrolizumab and chemotherapy produced a 63.1% objective response rate and 89.2% disease control rate in first-line stage 4 NSCLC, with a manageable safety profile supporting outpatient dosing.

check_boxKey Events · Product Development and Regulatory · EIKN

• EIK1001 Posts 63.1% ORR at ESMO

  In the efficacy-evaluable TeLuRide-005 population (n=65), EIK1001 plus pembrolizumab and chemotherapy produced a 63.1% objective response rate and 89.2% disease control rate at the October 1, 2026 data cutoff, with median follow-up of 17.2 months.

• Squamous Cohort Shows 100% DCR

  The squamous cohort (n=29) recorded 72.4% ORR and 100% DCR with a 12.9-month median duration of response at 12.7 months median follow-up; the non-squamous cohort (n=36) recorded 55.6% ORR and 80.6% DCR with an 11.2-month median DOR.

• Safety Supports Outpatient Dosing

  Grade 3 or higher treatment-related adverse events occurred in 48.6% of the 72 safety-evaluable participants and led to discontinuation in 6.9%; cytokine release syndrome events were all Grade 1 (n=5) or Grade 2 (n=2), with no Grade 3 or higher events and no treatment-related deaths.

• Registrational Trial Dose Decision in 2H 2027

  The Phase 2/3 TeLuRide-008 trial of EIK1001 in stage 4 NSCLC is actively enrolling, with a prespecified interim analysis to select the dose for the remainder of the trial expected in the second half of 2027.

auto_awesomeAnalysis · EIKN · Life Sciences

For a company this size, the updated TeLuRide-005 data for lead asset EIK1001 in first-line stage 4 NSCLC are strong enough to matter. In the pooled efficacy-evaluable population, the combination showed a 63.1% objective response rate and 89.2% disease control rate; the squamous cohort reached 72.4% ORR and 100% DCR with a 12.9-month median duration of response. Just as important, the tolerability profile — 48.6% Grade 3+ treatment-related adverse events, 6.9% discontinuations, and only low-grade cytokine release syndrome — supports outpatient systemic dosing, the differentiator Eikon is pitching against prior TLR7/8 therapies. The read-through is to TeLuRide-008, the ongoing Phase 2/3 registrational trial, where a dose-selection interim analysis is expected in the second half of 2027. Until then this is encouraging mid-stage data, not a regulatory event, and the company still carries a $171.4 million quarterly net loss and an unremediated material weakness previously disclosed in its Q2 10-Q.